The Innovative Medicines Initiative (IMI), now the Innovative Health Initiative (IHI), funds promising projects across Europe to turn health research into real benefits for patients and society. However, many of these initiatives struggle to maintain impact once EU funding ends. Despite general recognition of the need for financial and organisational sustainability, there is a lack…
The success of multinational pediatric clinical trials depends on efficient, high-quality, and scalable trial support services. From 2018 to 2025, the conect4children (c4c) network – a public-private partnership funded by the Innovative Medicines Initiative 2 – brought together 10 pharmaceutical companies and 33 academic and third-sector organizations to develop such services across 220+ sites in…
We are working to ensure children have the same rights as adults to access high quality, evidence-based medicines and health care services. We are fully committed to increasing high quality paediatric research.
We are working to ensure children have the same rights as adults to access high quality, evidence-based medicines and health care services. We are fully committed to increasing high quality paediatric research.
Since the announcement of the conect4children (c4c) Consortium’s first portfolio of research studies in April 2019, it is with regret that we inform you the Matrix-directed therapy in children with osteogenesis imperfecta (MOI) study, will no longer feature as part of the c4c portfolio of studies. The c4c Consortium undertook a competitive selection process of…
One of the goals of the c4c project is to boost the quality of data gathered from the clinical trials run through the c4c project. This will provide us with information on how the c4c network is performing. Fondazione Gianni Benzi Onlus and Janssen Pharmaceutical NV are working to design and integrate IT systems and…
The European Joint Programme for Rare Diseases has announced that 2020 will see the launch of a new funding call in pre-clinical research to develop effective therapies for rare diseases. The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project…
